High-dose chemotherapy and stem cell transplantation for advanced testicular cancer

References

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin.60(5), 277–300 (2010).
   PubMed Web of Science ®Google Scholar
• Einhorn LH. Testicular cancer as a model for a curable neoplasm: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res.41(9 Pt 1), 3275–3280 (1981).
   PubMed Web of Science ®Google Scholar
• Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann. Intern. Med.87(3), 293–298 (1977).
   PubMed Web of Science ®Google Scholar
• Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ. Medical treatment of advanced testicular cancer. JAMA299(6), 672–684 (2008).
   PubMed Web of Science ®Google Scholar
• International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J. Clin. Oncol.15(2), 594–603 (1997).
   PubMed Web of Science ®Google Scholar
• Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N. Engl. J. Med.316(23), 1435–1440 (1987).
   PubMed Web of Science ®Google Scholar
• Hinton S, Catalano PJ, Einhorn LH et al. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial. Cancer97(8), 1869–1875 (2003).
   PubMed Web of Science ®Google Scholar
• Kondagunta GV, Bacik J, Donadio A et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J. Clin. Oncol.23(27), 6549–6555 (2005).
   PubMed Web of Science ®Google Scholar
• Loehrer PJ Sr, Einhorn LH, Williams SD. VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. J. Clin. Oncol.4(4), 528–536 (1986).
   PubMed Web of Science ®Google Scholar
• Dicke KA, McCredie KB, Stevens EE, Spitzer G, Bottino JC. Autologous bone marrow transplantation in a case of acute adult leukemia. Transplant. Proc.9(1), 193–195 (1977).
   PubMed Web of Science ®Google Scholar
• Dicke KA, Zander A, Spitzer G et al. Autologous bone-marrow transplantation in relapsed adult acute leukaemia. Lancet1(8115), 514–517 (1979).
   PubMed Web of Science ®Google Scholar
• Graze PR, Gale RP. Autotransplantation for leukemia and solid tumors. Transplant. Proc.10(1), 177–184 (1978).
   PubMed Web of Science ®Google Scholar
• Dicke KA, McCredie KB, Spitzer G et al. Autologous bone marrow transplantation in patients with adult acute leukemia in relapse. Transplantation26(3), 169–173 (1978).
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Herzig GP, Graw RG et al. Study of cell dose and storage time on engraftment of cryopreserved autologous bone marrow in a canine model. Transplantation26(4), 245–248 (1978).
   PubMedGoogle Scholar
• Appelbaum FR, Herzig GP, Ziegler JL, Graw RG, Levine AS, Deisseroth AB. Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma. Blood52(1), 85–95 (1978).
   PubMed Web of Science ®Google Scholar
• Bunn PA Jr, Cohen MH, Ihde DC, Fossieck BE Jr, Matthews MJ, Minna JD. Advances in small cell bronchogenic carcinoma. Cancer Treat. Rep.61(3), 333–342 (1977).
   PubMedGoogle Scholar
• Spitzer G, Dicke KA, Litam J et al. High-dose combination chemotherapy with autologous bone marrow transplantation in adult solid tumors. Cancer45(12), 3075–3085 (1980).
   PubMed Web of Science ®Google Scholar
• Blijham G, Spitzer G, Litam J et al. The treatment of advanced testicular carcinoma with high dose chemotherapy and autologous marrow support. Eur. J. Cancer17(4), 433–441 (1981).
   PubMed Web of Science ®Google Scholar
• Fukuda M, Kojima S, Matsumoto K, Matsuyama T. Autotransplantation of peripheral blood stem cells mobilized by chemotherapy and recombinant human granulocyte colony-stimulating factor in childhood neuroblastoma and non-Hodgkin’s lymphoma. Br. J. Haematol.80(3), 327–331 (1992).
   PubMed Web of Science ®Google Scholar
• Gore ME, Calvert AH, Smith LE. High-dose carboplatin in the treatment of lung cancer and mesothelioma: a Phase I dose escalation study. Eur. J. Cancer Clin. Oncol.23(9), 1391–1397 (1987).
   PubMedGoogle Scholar
• Lee EJ, Egorin MJ, Van Echo DA, Cohen AE, Tait N, Schiffer CA. Phase I and pharmacokinetic trial of carboplatin in refractory adult leukemia. J. Natl Cancer Inst.80(2), 131–135 (1988).
   PubMed Web of Science ®Google Scholar
• Shea TC, Flaherty M, Elias A et al. A Phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J. Clin. Oncol.7(5), 651–661 (1989).
   PubMed Web of Science ®Google Scholar
• Wolff SN, Johnson DH, Hainsworth JD, Greco FA. High-dose VP-16–213 monotherapy for refractory germinal malignancies: a Phase II study. J. Clin. Oncol.2(4), 271–274 (1984).
   PubMed Web of Science ®Google Scholar
• Buckner CD, Clift RA, Fefer A et al. High-dose cyclophosphamide (NSC-26271) for the treatment of metastatic testicular neoplasms. Cancer Chemother. Rep.58(5 Pt 1), 709–714 (1974).
   PubMedGoogle Scholar
• Mulder PO, de Vries EG, Koops HS et al. Chemotherapy with maximally tolerable doses of VP 16–213 and cyclophosphamide followed by autologous bone marrow transplantation for the treatment of relapsed or refractory germ cell tumors. Eur. J. Cancer Clin. Oncol.24(4), 675–679 (1988).
   PubMedGoogle Scholar
• Nichols CR, Tricot G, Williams SD et al. Dose-intensive chemotherapy in refractory germ cell cancer – a Phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J. Clin. Oncol.7(7), 932–939 (1989).
   PubMed Web of Science ®Google Scholar
• Broun ER, Nichols CR, Kneebone P et al. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann. Intern. Med.117(2), 124–128 (1992).
   PubMed Web of Science ®Google Scholar
• Siegert W, Beyer J, Strohscheer I et al. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a Phase I/II study. The German Testicular Cancer Cooperative Study Group. J. Clin. Oncol.12(6), 1223–1231 (1994).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Mazumdar M, Bosl GJ, Bajorin DF, Amsterdam A, Vlamis V. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity. J. Clin. Oncol.14(4), 1098–1105 (1996).
   PubMed Web of Science ®Google Scholar
• Rick O, Bokemeyer C, Beyer J et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J. Clin. Oncol.19(1), 81–88 (2001).
   PubMed Web of Science ®Google Scholar
• Feldman DR, Sheinfeld J, Bajorin DF et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J. Clin. Oncol.28(10), 1706–1713 (2010).
   PubMed Web of Science ®Google Scholar
• Nichols CR, Andersen J, Lazarus HM et al. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol. J. Clin. Oncol.10(4), 558–563 (1992).
   PubMed Web of Science ®Google Scholar
• Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N. Engl. J. Med.357(4), 340–348 (2007).
   PubMed Web of Science ®Google Scholar
• Broun ER, Nichols CR, Tricot G, Loehrer PJ, Williams SD, Einhorn LH. High-dose carboplatin/VP-16 plus ifosfamide with autologous bone marrow support in the treatment of refractory germ cell tumors. Bone Marrow Transplant.7(1), 53–56 (1991).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bosl GJ. High-dose chemotherapy for resistant germ cell tumors: recent advances and future directions. J. Natl Cancer Inst.84(22), 1703–1709 (1992).
   PubMed Web of Science ®Google Scholar
• Droz JP, Kramar A, Pico JL. Prediction of long-term response after high-dose chemotherapy with autologous bone marrow transplantation in the salvage treatment of non-seminomatous germ cell tumours. Eur. J. Cancer29A(6), 818–821 (1993).
   PubMedGoogle Scholar
• Beyer J, Kramar A, Mandanas R et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J. Clin. Oncol.14(10), 2638–2645 (1996).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bajorin DF, Schwartz LH et al. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J. Clin. Oncol.12(11), 2277–2283 (1994).
   PubMed Web of Science ®Google Scholar
• Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J. Natl Cancer Inst.86(20), 1517–1524 (1994).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Mazumdar M, Sheinfeld J et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J. Clin. Oncol.18(6), 1173–1180 (2000).
   PubMed Web of Science ®Google Scholar
• Kondagunta GV, Bacik J, Sheinfeld J et al. Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J. Clin. Oncol.25(1), 85–90 (2007).
   PubMed Web of Science ®Google Scholar
• Pico JL, Rosti G, Kramar A et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann. Oncol.16(7), 1152–1159 (2005).
   PubMed Web of Science ®Google Scholar
• Lorch A, Kollmannsberger C, Hartmann JT et al. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J. Clin. Oncol.25(19), 2778–2784 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Gulati SC, Crown JP et al. High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated. Cancer69(2), 550–556 (1992).
   PubMed Web of Science ®Google Scholar
• Bhatia S, Abonour R, Porcu P et al. High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J. Clin. Oncol.18(19), 3346–3351 (2000).
   PubMed Web of Science ®Google Scholar
• Rick O, Beyer J, Kingreen D et al. High-dose chemotherapy in germ cell tumours: a large single centre experience. Eur. J. Cancer34(12), 1883–1888 (1998).
   PubMed Web of Science ®Google Scholar
• Lorch A, Mollevi C, Kramar A et al. Conventional-dose versus high-dose chemotherapy in relapsed or refractory male germ-cell tumors: a retrospective study in 1594 patients. J. Clin. Oncol.29(16), 2178–2184 (2010).
   Google Scholar
• Lorch A, Beyer J, Bascoul-Mollevi C et al. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J. Clin. Oncol.28(33), 4906–4911 (2010).
   PubMed Web of Science ®Google Scholar
• Saxman SB, Nichols CR, Einhorn LH. Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors: the Indiana University experience. J. Clin. Oncol.12(7), 1390–1393 (1994).
   PubMedGoogle Scholar
• Broun ER, Nichols CR, Einhorn LH, Tricot GJ. Salvage therapy with high-dose chemotherapy and autologous bone marrow support in the treatment of primary nonseminomatous mediastinal germ cell tumors. Cancer68(7), 1513–1515 (1991).
   PubMedGoogle Scholar
• Linkesch W, Greinix HT, Hocker P, Krainer M, Wagner AP. Longterm follow up of Phase I/II trial of ultra-high carboplatin, VP-16, cyclophosphamide with ABMT in refractory or relapsed NSGCT. Proc. Am. Soc. Clin. Oncol.12, 232 (1993).
   Google Scholar
• Lorch A, Beyer J, Mollevi C et al.; for the International Group on Prognostic Factors in Relapsed or Refractory Germ-Cell T. Prognostic factors in relapsed or refractory male germ cell tumors: results from an international study of 1,593 patients. Am. Soc. Clin. Oncol.27(Suppl. 15) (2009) (Abstract 5030).
   PubMedGoogle Scholar
• Vaena DA, Abonour R, Einhorn LH. Long-term survival after high-dose salvage chemotherapy for germ cell malignancies with adverse prognostic variables. J. Clin. Oncol.21(22), 4100–4104 (2003).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Mazumdar M, Gulati SC et al. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J. Natl Cancer Inst.85(22), 1828–1835 (1993).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Mazumdar M, Bajorin DF, Bosl GJ, Lyn P, Vlamis V. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J. Clin. Oncol.15(7), 2546–2552 (1997).
   PubMed Web of Science ®Google Scholar
• Decatris MP, Wilkinson PM, Welch RS, Metzner M, Morgenstern GR, Dougall M. High-dose chemotherapy and autologous haematopoietic support in poor risk non-seminomatous germ-cell tumours: an effective first-line therapy with minimal toxicity. Ann. Oncol.11(4), 427–434 (2000).
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Kollmannsberger C, Metzner B et al. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended Phase I/II study of the German Testicular Cancer Study Group. J. Clin. Oncol.21(22), 4083–4091 (2003).
   PubMed Web of Science ®Google Scholar
• Droz JP, Pico JL, Ghosn M et al. A Phase II trial of early intensive chemotherapy with autologous bone marrow transplantation in the treatment of poor prognosis non seminomatous germ cell tumors. Bull. Cancer79(5), 497–507 (1992).
   PubMed Web of Science ®Google Scholar
• Hartmann JT, Gauler T, Metzner B et al. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group. J. Clin. Oncol.25(36), 5742–5747 (2007).
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Kollmannsberger C, Meisner C et al. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched-pair analysis. J. Clin. Oncol.17(11), 3450–3456 (1999).
   PubMed Web of Science ®Google Scholar
• Chevreau C, Droz JP, Pico JL et al. Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Preliminary results of a French randomized trial. Eur. Urol.23(1), 213–217 (1993).
   PubMed Web of Science ®Google Scholar
• Droz JP, Kramar A, Biron P et al. Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial. Eur. Urol.51(3), 739–746; discussion 747–738 (2007).
   PubMed Web of Science ®Google Scholar
• Daugaard G, Skoneczna A, Aass N et al. A randomized Phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, ifosfamide (VIP) plus stem cell support in males with poor prognosis germ cell cancer (GCC): an intergroup study of EORTC, GTCSG, and Grupo Germinal. Ann. Oncol.22(5), 1054–1061 (2010).
   PubMedGoogle Scholar
• Motzer RJ, Nichols CJ, Margolin KA et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J. Clin. Oncol.25(3), 247–256 (2007).
   PubMed Web of Science ®Google Scholar
• Nichols CR, Williams SD, Loehrer PJ et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J. Clin. Oncol.9(7), 1163–1172 (1991).
   PubMed Web of Science ®Google Scholar
• Olofsson S, Dahl O, Jerkeman M et al. Individualized intensification of treatment based on tumor marker decline in metastatic nonseminomatous germ cell testicular cancer (NSGCT): a report from the Swedish Norwegian Testicular Cancer Group, SWENOTECA. J. Clin. Oncol.27(15s) (2009) (Abstract 5015).
   Google Scholar
• Advani R, Chao NJ, Horning SJ et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma. Ann. Intern, Med.116(3), 183–189 (1992).
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Prentice HG, Bacigalupo A et al. Placebo-controlled Phase III trial of lenograstim in bone-marrow transplantation. Lancet343(8899), 696–700 (1994).
   PubMed Web of Science ®Google Scholar
• Gorin NC, Coiffier B, Hayat M et al. Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin’s lymphoma: a double-blind placebo-controlled trial. Blood80(5), 1149–1157 (1992).
   PubMed Web of Science ®Google Scholar
• Khwaja A, Linch DC, Goldstone AH et al. Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a British National Lymphoma Investigation double-blind, placebo-controlled trial. Br. J. Haematol.82(2), 317–323 (1992).
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Rabinowe SN, Singer JW et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N. Engl. J. Med.324(25), 1773–1778 (1991).
   PubMed Web of Science ®Google Scholar
• Beyer J, Schwella N, Zingsem J et al. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. J. Clin. Oncol.13(6), 1328–1335 (1995).
   PubMed Web of Science ®Google Scholar
• Kondagunta GV, Motzer RJ. Chemotherapy for advanced germ cell tumors. J. Clin. Oncol.24(35), 5493–5502 (2006).
   PubMedGoogle Scholar
• Dubs A, Jacky E, Stahel R, Taverna C, Honegger H. Ototoxicity in patients with dose-intensive therapy for cisplatin-resistant germ cell tumors. J. Clin. Oncol.22(6), 1158; author reply 1158–1159 (2004).
   PubMed Web of Science ®Google Scholar
• Donadio AC, Motzer RJ, Bajorin DF et al. Chemotherapy for teratoma with malignant transformation. J. Clin. Oncol.21(23), 4285–4291 (2003).
   PubMed Web of Science ®Google Scholar
• Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol.7(11), 1748–1756 (1989).
   PubMed Web of Science ®Google Scholar
• Jelliffe RW. Letter: Creatinine clearance: bedside estimate. Ann. Intern. Med.79(4), 604–605 (1973).
   PubMed Web of Science ®Google Scholar